Axsome Therapeutics Stock Jumped: April Rally and What It Means for Investors
Axsome Therapeutics rode a powerful April rally driven by Auvelity performance and pipeline momentum. This article br...
Understand the compelling reasons to get a no annual fee travel card. Enjoy perks without the extra charges.
26,540 articlesAxsome Therapeutics rode a powerful April rally driven by Auvelity performance and pipeline momentum. This article br...
A single AI stock could outperform the rest on Nasdaq by the end of 2026. This article breaks down why that might hap...
Investors are buzzing as SAIC reports stronger-than-expected results and a growing federal pipeline. This article bre...
Meta Platforms is betting big on AI and cloud tech, fueling debate over whether meta's spending spree reckless moves ...
WD-40 has evolved from a single iconic spray into a disciplined maintenance-products company. This deep dive explains...
Palantir trades at lofty multiples, but its growth engine is real. This piece weighs the high valuation against the b...
As AI demands surge, CoreWeave positions itself as a specialized cloud provider for GPU compute. This article digs in...
KBR has endured a tough year, with the stock fallen this past year by about 45%. A fresh stake worth $24 million from...
Nvidia looks like genius as AI demand pushes data center capital spending higher. This piece breaks down why the comp...
A two-year income lookback determines Medicare premiums for next year, catching early IRA inheritors by surprise and ...
OpenAI Pushes Ahead With Controversial Chat Modes Safety highlights a bold move in AI product design and the risk it ...
Accenture stands out as a strong contender in the consulting arena. This article digs into why investors should pay a...